$24.665
-1.035[-4.03%]
Last update: 9:42AM Get Real Time Here
Protagonist Therapeutics
(NASDAQ:PTGX)Latest News for Protagonist Therapeutics Stock (NASDAQ:PTGX)
Protagonist Therapeutics Stock (NASDAQ: PTGX)
Categories: All
Monday, March 11, 2024
- HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Maintains $38 Price TargetBenzinga Newsdesk - Mar 11, 2024, 12:15PM
- JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $42 Price TargetBenzinga Newsdesk - Mar 11, 2024, 10:12AM
- Protagonist Therapeutics Announced A Late-breaking Presentation At The American Academy Of Dermatology 2024 Annual Meeting With Results From The Phase 2b FRONTIER 2 Long-term Extension Study Evaluating JNJ-2113 For Moderate-to-severe Plaque PsoriasisBenzinga Newsdesk - Mar 11, 2024, 7:40AM
Wednesday, February 28, 2024
Tuesday, February 27, 2024
Wednesday, February 21, 2024
Thursday, February 01, 2024
- Protagonist Therapeutics shares are trading higher after the company and Takeda announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide.Benzinga Newsdesk - Feb 1, 2024, 2:12PM
- Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?Vandana Singh - Feb 1, 2024, 2:07PM
Wednesday, January 31, 2024
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga Insights - Jan 31, 2024, 4:31PM
- Protagonist Therapeutics shares are trading higher after the company and Takeda announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide.Benzinga Newsdesk - Jan 31, 2024, 4:29PM
- Takeda And Protagonist Therapeutics, Inc. Enter Worldwide License And Collaboration Agreement For Rusfertide; Takeda To Make Upfront Payment Of $300M At ClosingBenzinga Newsdesk - Jan 31, 2024, 4:08PM
Tuesday, December 12, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
Tuesday, October 31, 2023
Monday, October 30, 2023
Tuesday, October 24, 2023
Friday, October 20, 2023
Tuesday, October 10, 2023
Monday, October 09, 2023
Monday, September 25, 2023
Friday, August 04, 2023
Thursday, August 03, 2023
Thursday, July 27, 2023
Monday, July 10, 2023
Thursday, July 06, 2023
- Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data ImpressiveVandana Singh - Jul 6, 2023, 3:48PM
- Expert Ratings for Protagonist TherapeuticsBenzinga Insights - Jul 6, 2023, 2:01PM
- Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For ThursdayLisa Levin - Jul 6, 2023, 8:43AM
- JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $35Benzinga Newsdesk - Jul 6, 2023, 7:44AM
Wednesday, July 05, 2023
Tuesday, July 04, 2023
Monday, July 03, 2023
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Jul 3, 2023, 1:37PM
- Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's SessionLisa Levin - Jul 3, 2023, 12:52PM
- Piper Sandler Reiterates Overweight on Protagonist Therapeutics, Maintains $35 Price TargetBenzinga Newsdesk - Jul 3, 2023, 12:45PM
- Protagonist Therapeutics Option Alert: Jul 21 $22.5 Calls Sweep (4) near the Ask: 301 @ $1.556 vs 700 OI; Earnings 8/3 After Close [est] Ref=$21.01Charles Gross - Jul 3, 2023, 12:14PM
- BTIG Reiterates Buy on Protagonist Therapeutics, Maintains $41 Price TargetBenzinga Newsdesk - Jul 3, 2023, 12:11PM
- AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On MondayLisa Levin - Jul 3, 2023, 10:41AM
- US Stocks Mixed; Dow Falls Over 50 PointsLisa Levin - Jul 3, 2023, 9:58AM